title: The overlapping roles of antimicrobial peptides and complement in recruitment and activation of tumor-associated inflammatory cells.
abstract: Antimicrobial peptides (AMPs) represent a group of small (6-100 amino acids), biologically active molecules, which are produced by plants, mammals, and microorganisms (1). An important element of the innate immune response, AMP, possesses potent antibiotic, antifungal, and antiviral activities. Furthermore, AMP may be involved in a number of other processes such as angiogenesis and modulation of the immune response such as stimulation of chemokines and chemotaxis of leukocytes. AMPs have been proposed as alternative therapies for infectious diseases. AMP may also exert cytotoxic activity against tumor cells. Further understanding of the biological function of these peptides during tumor development and progression may aid in the development of novel anti-tumor therapies with refined application of innate molecules. AMP and complement have distinct roles to play in shaping the microenvironment (Table 1). Components of the complement system are integral contributors in responding to infection and sterile inflammation. Moreover, complement plays a role in the trafficking of cells in the tumor microenvironment, and thereby possibly in the immune response to cancer. This article will try to outline characteristics of AMP and complement in mobilization and recruitment of cells in tumor microenvironment.
authors: Department of Infection, Immunity and Inflammation, College of Medicine, Biological Sciences and Psychology, University of Leicester , Leicester , UK ; The Ministry of Higher Education , Baghdad , Iraq.
authors: Izzat A M
authors: IA
authors: Al-Rayahi
authors: Department of Infection, Immunity and Inflammation, College of Medicine, Biological Sciences and Psychology, University of Leicester , Leicester , UK ; The Ministry of Higher Education , Baghdad , Iraq.
authors: Raghad H H
authors: RH
authors: Sanyi
keywords: anti-tumor activity; c5a; cathelicidins; cell recruitment and activation; defensins
references: FEBS Lett. 1994 Dec 19;356(2-3):169-73
references: 7805831
references: Am J Pathol. 2002 Apr;160(4):1311-24
references: 11943716
references: Cancer Res. 2012 Dec 15;72(24):6512-23
references: 23100468
references: Int J Pept. 2013;2013:675391
references: 23935642
references: PLoS One. 2010 Jun 08;5(6):e10993
references: 20544025
references: J Burns Wounds. 2007 Jan 10;5:e10
references: 17235375
references: Hum Gene Ther. 2014 Jan;25(1):63-72
references: 24134464
references: Semin Immunol. 2013 Feb;25(1):54-64
references: 23706991
references: Chem Phys Lipids. 2011 Nov;164(8):766-81
references: 21945565
references: Trends Immunol. 2002 Oct;23(10):485-91
references: 12297420
references: Oncogene. 2014 May 22;33(21):2709-16
references: 23812430
references: Int J Oncol. 2003 Jan;22(1):93-8
references: 12469190
references: Neoplasia. 2012 Nov;14(11):994-1004
references: 23226093
references: Lab Invest. 2003 Apr;83(4):501-5
references: 12695553
references: Mol Immunol. 1997 Aug;34(11):809-16
references: 9444979
references: Am J Transl Res. 2012;4(4):376-89
references: 23145206
references: Urol Oncol. 2006 Mar-Apr;24(2):97-108
references: 16520271
references: Inflamm Res. 2010 Nov;59(11):897-905
references: 20517706
references: J Proteomics. 2009 Aug 20;72(6):918-27
references: 19186224
references: Cell Mol Life Sci. 2001 Jun;58(7):978-89
references: 11497243
references: Int J Mol Med. 2010 Mar;25(3):307-13
references: 20127033
references: Nat Immunol. 2008 Nov;9(11):1225-35
references: 18820683
references: Leukemia. 2012 Apr;26(4):736-45
references: 21931324
references: Cancer Invest. 2009 Jun;27(5):575-81
references: 19219676
references: Science. 1999 Oct 15;286(5439):525-8
references: 10521347
references: Mol Immunol. 2007 Jul;44(14):3608-14
references: 17448537
references: Anticancer Res. 2004 Nov-Dec;24(6):4051-7
references: 15736451
references: Mol Immunol. 2008 Feb;45(3):839-48
references: 17868871
references: J Immunol. 2012 Sep 15;189(6):2985-94
references: 22914051
references: Oncotarget. 2014 Apr 15;5(7):1856-68
references: 24732135
references: Anticancer Res. 2002 Sep-Oct;22(5):2811-6
references: 12530001
references: Nat Med. 2004 Sep;10(9):950-8
references: 15334073
references: Curr Med Chem. 2014;21(21):2392-400
references: 24524763
references: Int J Oncol. 2014 Sep;45(3):1059-64
references: 24969834
references: J Leukoc Biol. 2004 Jan;75(1):39-48
references: 12960280